Chess theory

Max Pawn's Michael Mack Wins Pawnbroker of the Year from National Pawnbrokers Association

Retrieved on: 
Thursday, July 15, 2021
Loans, Pawnbroker, Repurposing, Economy, Money, Personal finance, Pawn shops, Pawn Stars, Chess theory

FORT WORTH, TEXASand LAS VEGAS, July 15, 2021 /PRNewswire/ -- Las Vegas' world famous luxury reseller, Max Pawn, is proud to announce that owner Michael Mack has been recognized as Pawn Broker of the Year by the National Pawnbrokers Association, as reported by Authentic PR.

Key Points: 
  • FORT WORTH, TEXASand LAS VEGAS, July 15, 2021 /PRNewswire/ -- Las Vegas' world famous luxury reseller, Max Pawn, is proud to announce that owner Michael Mack has been recognized as Pawn Broker of the Year by the National Pawnbrokers Association, as reported by Authentic PR.
  • "Winning Pawn Broker of the Year is a huge honor and something I'm proud to bring home to Max Pawn," say Max Pawn owner Michael Mack.
  • About Max Pawn: Founded on the principles of honesty, good value and great customer service, Las Vegas' Max Pawn is the city's go-to consignment and reseller.
  • Led by fourth- generation pawn broker Michael Mack, Max Pawn offers an award-winning experience to every customer.

Checkmate Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides an Update on Recent Progress

Retrieved on: 
Friday, November 13, 2020
Chess, Game theory, Health, Checkmate, Chess theory, Pharmaceutical industry in China, Melanoma

CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals , Inc. (NASDAQ: CMPI) (Checkmate), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced third quarter 2020 financial results and provided an update on recent progress.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals , Inc. (NASDAQ: CMPI) (Checkmate), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced third quarter 2020 financial results and provided an update on recent progress.
  • These data continue to demonstrate the clinical activity of CMP-001 in combination with anti-PD-1 antibodies in patients with melanoma.
  • Research and development expenses (R&D): R&D expenses were $6.7 million for the quarter ended September 30, 2020, compared to $5.1 million for the quarter ended September 30, 2019.
  • General and administration expenses (G&A): G&A expenses were $3.2 million for the quarter ended September 30, 2020, compared to $1.2 million for the quarter ended September 30, 2019.

NeuroSigma Receives Bridge Financing from Checkmate Capital

Retrieved on: 
Monday, September 21, 2020
Chess, Game theory, Songs, Checkmate, Chess theory

LOS ANGELES, Sept. 21, 2020 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. (NeuroSigma), a Los Angeles-based bioelectronics company, is pleased to announce the receipt of bridge equity financing from Checkmate Capital Group (Checkmate Capital) of Pasadena, California.

Key Points: 
  • LOS ANGELES, Sept. 21, 2020 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. (NeuroSigma), a Los Angeles-based bioelectronics company, is pleased to announce the receipt of bridge equity financing from Checkmate Capital Group (Checkmate Capital) of Pasadena, California.
  • The new bridge financing will assist NeuroSigmas transition to the commercial stage of its development.
  • In addition to investing in NeuroSigma, Checkmate Capital has agreed to provide certain commercial and transactional services to NeuroSigma with regard to international licensing, partnerships and other commercial initiatives.
  • We are delighted by Checkmate Capitals investment and appreciate the collaborative working relationship we have developed with the Checkmate Capital team, said NeuroSigmas CEO, Leon Ekchian, Ph.D.

Checkmate Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides an Update on Recent Progress

Retrieved on: 
Friday, September 18, 2020
Chess, Game theory, Pharmaceuticals policy, Checkmate, Chess theory, Pharmaceutical industry in China

CAMBRIDGE, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (Checkmate), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, today announced second quarter 2020 financial results and provided an update on recent progress.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (Checkmate), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, today announced second quarter 2020 financial results and provided an update on recent progress.
  • In August 2020, Checkmate closed its initial public offering of 5,000,000 shares of common stock at $15 per share.
  • Research and development expenses (R&D): R&D expenses were $6.5 million for the quarter ended June 30, 2020, compared to $5.8 million for the quarter ended June 30, 2019.
  • General and administration expenses (G&A): G&A expenses were $1.8 million for the quarter ended June 30, 2020, compared to $1.1 million for the quarter ended June 30, 2019.

Endgame Researchers to Speak at 2019 Black Hat, BSides, and DEF CON: AI Village in Las Vegas

Retrieved on: 
Monday, August 5, 2019
Chess, Hacker conventions, Chess theory, DEF CON, Endgame, Chess endgame, EG, Black Hat Briefings, Endpoint

LAS VEGAS, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Endgame, the leader in endpoint security, today announced its schedule for the upcoming 2019 Black Hat, BSides and DEF CON 27 conferences from Aug. 7-11.

Key Points: 
  • LAS VEGAS, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Endgame, the leader in endpoint security, today announced its schedule for the upcoming 2019 Black Hat, BSides and DEF CON 27 conferences from Aug. 7-11.
  • Endgames researchers will be presenting on a variety of topics to engage the community in education and collaboration.
  • The village will include several educational talks and panels to demystify machine learning so security practitioners can use and understand AI tools to thwart sophisticated adversaries.
  • Ultimately, we all benefit when theres an open discourse on emerging trends and proposed solutions, said Hyrum Anderson, Chief Scientist at Endgame.